Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
तुलना करने के लिए मीट्रिक्स | PHAR | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPHARपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 2,974.9x | 4.1x | −0.5x | |
PEG अनुपात | 29.51 | −0.07 | 0.00 | |
क़ीमत/बुक | 4.3x | 1.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 3.1x | 3.0x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | 57.8% | 47.3% | 45.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 14.8% | 4.9% | अनलॉक करें |